名稱 | BCR-ABL1 E255K/BaF3 |
型號 | CBP73318 |
報(bào)價(jià) | ![]() |
特點(diǎn) | BCR-ABL1 [E255K]/BaF3 |
產(chǎn)品搜索
相關(guān)文章
- 【盤點(diǎn)】癌癥免疫檢查點(diǎn)療法的現(xiàn)狀與展望
- 新加坡科學(xué)家找到治療侵襲性卵巢癌的新可能
- BCR-ABL激酶抑制劑細(xì)胞篩選模型
- PDGFRA靶點(diǎn)藥物細(xì)胞篩選模型
- 實(shí)驗(yàn)?zāi)芊裰貜?fù)仍在持續(xù):誰來給韓春雨事件畫上句號?
- 人結(jié)腸癌細(xì)胞株試驗(yàn)要點(diǎn)及說明
- 【靶點(diǎn)模型+診斷質(zhì)控】EGFR vIII的藥物開發(fā)和診斷
- 喝熱茶或使食管癌風(fēng)險(xiǎn)增加5倍
- Nature:繞過Ras激酶“不可成藥性”的抗癌新思路
- 腫瘤細(xì)胞的熱敏感特性分析
聯(lián)系我們
電話:4008750250
號碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73318BCR-ABL1 E255K/BaF3

- 詳細(xì)內(nèi)容
CBP73318 | |
I. Introduction | |
Cell Line Name: | BCR-ABL1 [E255K]/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. | |
III. Representative Data | |
1.WB of BCR-ABL1 [E255K]/BaF3 | |
2.Sanger of BCR-ABL1 [E255K]/BaF3 Figure 2. BCR-ABL1 [E255K]/BaF3 Figure 3. BCR-ABL1 [E255K]/BaF3 Fusion | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 E255K Cells (C3). | |